Skip to content

Study on immune trajectory of the elderly after acute pulmonary infections

Study on immune trajectory of the elderly after acute pulmonary infections

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069793
Enrollment
Unknown
Registered
2023-03-26
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary infection in the elderly

Interventions

group of lung infection in elderly:no intervetion

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 120 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for acute pulmonary infection in (1) above; Patients or their families knew the content of the study and signed informed consent form voluntarily. (For the judgment criteria of acute pulmonary infection, reference was made to the 2016 edition of China Guidelines for the Diagnosis and Treatment of Adult Community-acquired Pneumonia: new or progressive pulmonary infiltrative lesion (onset time 10×109/L or < 4×109/L with or without left shift of nucleus; Recent cough, expectoration, or exacerbation of preexisting respiratory symptoms with purulent sputum with or without chest pain. 1)+2) ~ 5) above, except for pulmonary tuberculosis, pulmonary tumor, non-infectious pulmonary interstitial disease, pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophilic infiltration, pulmonary vasculitis, etc. )

Exclusion criteria

Exclusion criteria: Suffering from serious basic diseases, and the life expectancy is less than 1 year; Immunosuppressed patients, including the following: primary immunodeficiency; Active malignant tumors or malignant tumors within 1 year, excluding local skin cancer or patients with early stage cancer (such as stage I lung cancer); Tumor chemotherapy; CD4+ T cells of HIV infected patients 600mg; Receiving biological preparations, anti-rheumatic drugs for improving diseases or other immunosuppressive drugs); Long-term bedridden patients.

Design outcomes

Primary

MeasureTime frame
Mortality within 1 year;

Secondary

MeasureTime frame
Rehospitalization rate within 1year;Differences of immune indexes among different subgroups (Dead group VS alive group; Readmission group VS no-readmission group);Immune risk factors warning model for poor prognosis (death and re-hospitalization within one year).;

Countries

China

Contacts

Public ContactBaoming Fang/Jie Ma

Beijing Hospital

fbmlyh@sina.com+86 13521717976

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026